In one paragraphArticle in American journal of physiology. Renal physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Amanda J ClarkDivision of Pediatric Nephrology, Department of Pediatrics, University of Texas Southwestern, Children's Medical Center Dallas, Dallas, Texas, United States.ORCID 0000-0002-6550-730X Brenda Mendoza FloresDivision of Nephrology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, United States.
Marie Christelle SaadeDivision of Nephrology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, United States.
Kyle Q VuDivision of Pediatric Nephrology, Department of Pediatrics, University of Texas Southwestern, Children's Medical Center Dallas, Dallas, Texas, United States.
Isaac J PenceDivision of Nephrology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, United States.ORCID 0000-0002-5635-1374 Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States.ORCID 0000-0002-4348-2180 Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States.
Dawei BuTouchstone Diabetes Center, University of Texas Southwestern, Dallas, Texas, United States.
Philipp E SchererTouchstone Diabetes Center, University of Texas Southwestern, Dallas, Texas, United States.ORCID 0000-0003-0680-3392 Samir M ParikhDivision of Nephrology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, United States.ORCID 0000-0002-1038-981X Funding
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1MUT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeffrey M Zigman · 2022 to 2026
$7.4MTie2-driven vascular control in critical illnessR35HL139424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI PARIKH, SAMIR M · 2018 to 2024
$6.4MMitochondrial Biogenesis in Kidney DiseaseR01DK095072 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Samir M Parikh · 2012 to 2026
$5.3MElucidating the Role of NAD+ and PARylation in Nephron EndowmentK08DK138291 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Amanda J Clark · 2025 to 2026
$336kAmerican Society of Nephrology (ASN) Ben Lipps FellowshipCancer Prevention and Research Institute of Texas (CPRIT) RP190561HHS | NIH | NICHD | Pediatric Scientist Development Program (PSDP) K12HD000850HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) K08DK138291HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) R01DK095072NHLBI NIH HHS R35 HL139424NICHD NIH HHS K12 HD000850NIDDK NIH HHS K08 DK138291NIDDK NIH HHS P30 DK127984NIDDK NIH HHS R01 DK095072Welch Foundation (The Welch Foundation) AU-0042-20030616
6 · The paper itselfAbstract
Acute kidney injury (AKI) is prevalent among hospitalized patients. Novel biomarkers are needed to diagnose AKI and target therapies. Endotrophin (ETP) is a molecule released during collagen type VI formation that may promote injury and fibrosis. Although serum ETP elevation has been associated with adverse outcomes in AKI, urinary ETP has not been assessed in AKI, nor has ETP been evaluated in a pediatric population. Urine samples were collected from a tertiary children's hospital. Medical records were reviewed, and patients who met criteria were sorted into three categories:
Indexed as
Acute Kidney InjuryPeptide FragmentsAdolescentBiomarkersCase-Control StudiesChildChild, PreschoolCollagen Type VICreatinineFemaleHumansInfantMaleRetrospective StudiesBiomarkersCollagen Type VICreatinineendotrophinPeptide Fragmentsacute kidney injurybiomarkerendotrophinmetabolism
Identifiers
PMID41083270
PMCPMC12704364
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390